Protein biomarkers measured in cerebrospinal fluid (CSF) and plasma are widely used for diagnosis and monitoring of neurological disorders and are being applied increasingly in clinical trials to assess how novel therapies affect brain biology. However, measurements are influenced not only by underlying neurobiology but also by physiological differences between individuals — for example, compartment volumes and elimination kinetics — which introduce non-disease-related variability. Clinical-trial populations are often more homogeneous than real-world diagnostic cohorts, so understanding physiological contributors to variability is important to correctly interpret biomarker changes in trials.
The authors used paired baseline CSF and plasma data from four Phase III clinical trials — GRADUATE I and II, and CREAD and CREAD2 — restricted to amyloid-positive trial cohorts. They applied a mechanistic kinetic framework to quantify how much inter-individual variability in commonly used Alzheimer disease (AD) biomarkers arises from physiological factors versus neurobiological factors. The study analyzed only baseline, de-identified data from those trials; details beyond this were not reported in the source abstract.
The analysis used a mechanistic kinetic approach to partition observed inter-individual variability into components attributable to physiological processes (for example, compartmental volume and elimination kinetics) and those attributable to neurobiology (disease-related production, clearance, or pathology-related changes). This framework was also used to evaluate when normalizing one biomarker by another (ratio-based normalization) can reduce physiological variability and therefore improve biomarker performance in a trial context.
The biomarkers evaluated in the paired CSF and plasma data included Aβ40, Aβ42, p-tau181, t-tau, NfL, GFAP, sTREM2, and YKL-40. These are commonly used in AD research and clinical studies to reflect amyloid processing, tau pathology, neurodegeneration, astrocytic activation, and microglial activity.
In these amyloid-positive clinical-trial populations, the authors found that a large fraction of inter-individual variability could be attributed to physiological variability. The abstract emphasizes that physiological factors contributed substantially across the set of biomarkers studied, implying that non-neurobiological sources of variability are important to consider when interpreting baseline measurements and between-subject differences in trials.
The investigators evaluated normalization strategies that divide target biomarker concentrations by concentrations of Aβ40 or Aβ42. They report that normalizing biomarker values by Aβ40 or Aβ42 reduced physiological variability for some biomarkers. However, the effect was not uniform: the benefit of normalization depended on the biological compartment (CSF versus plasma) and on the specific clinical cohort. Thus, ratio-based normalization can reduce physiological noise in certain contexts, but it is not universally effective.
Using their mechanistic framework, the authors identify two conditions under which ratio-based normalization is most likely to improve biomarker performance:
The target and reference biomarkers strongly share physiological variability, meaning they are influenced similarly by non-neurobiological factors such as volume or elimination kinetics.
The target and reference biomarkers maintain independent neurobiological variability, so dividing one by the other does not remove or obscure disease-related signal that is specific to the target biomarker.
These two conditions provide a mechanistic explanation for why Aβ-based ratios are useful for some biomarkers but not optimal for others.
The findings advance understanding of sources of biomarker variability in clinical trials and supply a framework to decide when ratio-based normalization is likely to be informative. Applying such mechanistic reasoning can help trialists and analysts choose normalization strategies that reduce physiological noise while preserving neurobiological signal, thereby strengthening the utility of biomarkers for monitoring drug effects and disease processes in trial settings.
All authors are employees of F. Hoffmann-La Roche Ltd. The clinical trials from which datasets were drawn are registered (NCT03444870, NCT03443973, NCT02670083, NCT03114657). The preprint has not been peer reviewed and should not be used to guide clinical practice.
Clinical trial datasets analyzed in this study are de-identified. Qualified researchers may request access to individual patient–level clinical data through the indicated data request platform referenced in the source. The abstract does not provide additional dataset-level details in this summary.